STOCK TITAN
  1. Home
  2. Sec-filings
  3. GYRE
  4. [Form 4] GYRE THERAPEUTICS, INC. Insider Trading Activity

Director Dan Weng receives 40,000-share option grant at GYRE (NASDAQ: GYRE)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. director Dan Weng received a stock option grant covering 40,000 shares of common stock. The option has an exercise price of $5.95 per share and expires on June 10, 2036.

The award vests in 12 equal monthly installments through June 10, 2027, conditioned on continued service. After this grant, Weng holds stock options for 40,000 underlying shares directly, reflecting routine equity-based compensation rather than an open-market transaction.

Positive

  • None.

Negative

  • None.
Insider Weng Dan
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 40,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 40,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 40,000 shares Underlying GYRE common stock in new option award
Exercise price $5.95 per share Stock option strike price
Total options after grant 40,000 options Total derivative securities following transaction
Vesting schedule 12 monthly installments Vesting through June 10, 2027, subject to continued service
Expiration date June 10, 2036 Option term end date
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "5.9500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in 12 equal monthly installments financial
"which will vest in 12 equal monthly installments through June 10, 2027"
expiration date financial
"expiration_date: "2036-06-10T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: "Common Stock""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Weng Dan
(Last)(First)(Middle)
C/O GYRE THERAPEUTICS, INC.
12730 HIGH BLUFF DRIVE, SUITE 250
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$5.9506/10/2026A40,000 (1)06/10/2036Common Stock40,000$040,000D
Explanation of Responses:
1. This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.
/s/ Thomas Eastling, as attorney-in-fact for Dan Weng06/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did GYRE director Dan Weng report in this Form 4 filing?

Dan Weng reported receiving a stock option grant for 40,000 shares of GYRE common stock. The option is a compensation award, not an open-market trade, and gives him the right to buy shares at a fixed exercise price if it vests.

What are the key terms of Dan Weng’s GYRE stock option grant?

The grant covers 40,000 underlying GYRE common shares with a $5.95 exercise price and a June 10, 2036 expiration. These terms define how many shares he can buy, at what price, and how long the right lasts.

How does the GYRE stock option granted to Dan Weng vest over time?

The option vests in 12 equal monthly installments through June 10, 2027. Each month, a portion becomes exercisable, provided Weng continues serving the company through each vesting date, aligning ongoing service with equity compensation.

Is Dan Weng’s GYRE Form 4 transaction an open-market stock purchase or sale?

No, this Form 4 reports a compensation-related option grant, not an open-market buy or sell. Code “A” indicates a grant or award acquisition, meaning the company awarded options rather than Weng trading existing shares on the market.